Search | Clinical Trials Finder

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: LEXIVA (GW433908), Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more

Conditions: Peripheral Vascular Disease, Abdominal Aortic Aneurysm
Interventions: continuous intravenous insulin infusion; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Tract Infection, Head Injury, Laceration
Interventions: Video discharge instructions; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Clostridium Difficile
Interventions: Fecal Microbiota Preparation; Drug
Lead sponsor: Microbiome Health Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Naperville, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Leukemia, Lymphoma, Blood Disorders, Solid Tumors
Interventions: Ethanol lock therapy (ELT); Drug
Lead sponsor: Children's Hospital of Michigan; Other
Eligibility: 6 Months to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Immunization; Infection, Pregnancy Related, COVID-19
Interventions: VAX-MOM COVID-19 Intervention, Standard of Care; Behavioral · Other
Lead sponsor: University of Rochester; Other
Eligibility: Female only
Enrollment: 6,911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Trauma, Infection, Bone Fracture
Interventions: Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Herpes Zoster (HZ), Vascular Dementia
Interventions: Not listed
Lead sponsor: Center for Clinical Studies, Texas; Other
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Houston, Texas • Webster, Texas

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more

Conditions: Prevention of Zika Infection, Zika-Specific Immune Response
Interventions: VRC-ZKADNA085-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland

Conditions: HIV-1 Infection
Interventions: Niacin, Aspirin, Fenofibrate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Doravirine, 2 NRTIs, DOR/3TC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 4 Weeks to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: COVID-19
Interventions: CovX; Device
Lead sponsor: Dascena; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: HIV-1-infection
Interventions: Albuvirtide, 3BNC117, Baseline ART; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more

Conditions: COVID-19
Interventions: CareSuperb COVID-19 Antigen Home Test Kit; Device
Lead sponsor: AccessBio, Inc.; Other
Eligibility: 2 Years and older
Enrollment: 786 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infection
Interventions: Blood draw; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Aspergillos, Mucormye, Dimorphic, Other Molds, Non-Aspergillos, Non-Mucormycosis
Interventions: [18F]-Fluorocellobiose ([18F]FCB); Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Septic Shock
Interventions: LB1148, Placebo; Drug
Lead sponsor: Leading BioSciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 23 more

Conditions: Bacteremia
Interventions: Specimens that meet inclusion criteria; Device
Lead sponsor: Accelerate Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 731 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Tucson, Arizona • Hershey, Pennsylvania • Lewisville, Texas

Conditions: Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions: Hematopoietic Stem Cell Transplant; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 4 Months to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more

Conditions: Healthcare-acquired Infection
Interventions: Copper-alloy surfaced patient care objects; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination

Use of 5-Aminolevulinic Acid to Assess Bone and Tissue Profusion in Orthopaedic Infection Patients

A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.

Risk Factors, Costs, and Impacts of ED Boarding

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Classification of COVID-19 Infection in Posteroanterior Chest X-rays

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Clinical Performance Evaluation of the CareSuperb™ COVID-19 Antigen Home Test

Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

Efficacy Of Copper To Reduce Acquisition Of Microbes and Healthcare-acquired Infections